Jeremy P Harris1,2, Michelle M Chen2,3, Ryan K Orosco4, Davud Sirjani2,3, Vasu Divi2,3, Wendy Hara1. 1. Department of Radiation Oncology, Stanford University, Stanford, California. 2. Palo Alto Veterans Affairs Health Care System, Palo Alto, California. 3. Department of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, California. 4. Department of Head and Neck Surgery, University of California San Diego, San Diego.
Abstract
IMPORTANCE: Shortening the time from surgery to the start of radiation (TS-RT) is a consideration for physicians and patients. Although the National Comprehensive Cancer Network recommends radiation to start within 6 weeks, a survival benefit with this metric remains controversial. OBJECTIVE: To determine the association of delayed TS-RT with overall survival (OS) using a large cancer registry. DESIGN, SETTING, AND PARTICIPANTS: In this observational cohort study, 25 216 patients with nonmetastatic stages III to IV head and neck cancer were identified from the National Cancer Database (NCDB). EXPOSURES: Patients received definitive surgery followed by adjuvant radiation therapy, with an interval duration defined as TS-RT. MAIN OUTCOMES AND MEASURES: Overall survival as a function of TS-RT and the effect of clinicopathologic risk factors and accelerated fractionation. RESULTS: We identified 25 216 patients with nonmetastatic squamous cell carcinoma of the head and neck. There were 18 968 (75%) men and 6248 (25%) women and the mean (SD) age of the cohort was 59 (10.9) years. Of the 25 216 patients, 9765 (39%) had a 42-days or less TS-RT and 4735 (19%) had a 43- to 49-day TS-RT. Median OS was 10.5 years (95% CI, 10.0-11.1 years) for patients with a 42-days or less TS-RT, 8.2 years (95% CI, 7.4-8.6 years; absolute difference, -2.4 years, 95% CI, -1.5 to -3.2 years) for patients with a 43- to 49-day TS-RT, and 6.5 years (95% CI, 6.1-6.8 years; absolute difference, -4.1 years, 95% CI, -3.4 to -4.7 years) for those with a 50-days or more TS-RT. Multivariable analysis found that compared with a 42-days or less TS-RT, there was not a significant increase in mortality with a 43- to 49-day TS-RT (HR, 0.98; 95% CI, 0.93-1.04), although there was for a TS-RT of 50 days or more (HR, 1.07; 95% CI, 1.02-1.12). A significant interaction was identified between TS-RT and disease site. Subgroup effect modeling found that a delayed TS-RT of 7 days resulted in significantly worse OS for patients with tonsil tumors (HR, 1.22; 95% CI, 1.05-1.43) though not other tumor subtypes. Accelerated fractionation of 5.2 fractions or more per week was associated with improved survival (HR, 0.93; 95% CI, 0.87-0.99) compared with standard fractionation. CONCLUSIONS AND RELEVANCE: Delayed TS-RT of 50 days or more was associated with worse overall survival. The multidisciplinary care team should focus on shortening TS-RT to improve survival. Unavoidable delays may be an indication for accelerated fractionation or other dose intensification strategies.
IMPORTANCE: Shortening the time from surgery to the start of radiation (TS-RT) is a consideration for physicians and patients. Although the National Comprehensive Cancer Network recommends radiation to start within 6 weeks, a survival benefit with this metric remains controversial. OBJECTIVE: To determine the association of delayed TS-RT with overall survival (OS) using a large cancer registry. DESIGN, SETTING, AND PARTICIPANTS: In this observational cohort study, 25 216 patients with nonmetastatic stages III to IV head and neck cancer were identified from the National Cancer Database (NCDB). EXPOSURES: Patients received definitive surgery followed by adjuvant radiation therapy, with an interval duration defined as TS-RT. MAIN OUTCOMES AND MEASURES: Overall survival as a function of TS-RT and the effect of clinicopathologic risk factors and accelerated fractionation. RESULTS: We identified 25 216 patients with nonmetastatic squamous cell carcinoma of the head and neck. There were 18 968 (75%) men and 6248 (25%) women and the mean (SD) age of the cohort was 59 (10.9) years. Of the 25 216 patients, 9765 (39%) had a 42-days or less TS-RT and 4735 (19%) had a 43- to 49-day TS-RT. Median OS was 10.5 years (95% CI, 10.0-11.1 years) for patients with a 42-days or less TS-RT, 8.2 years (95% CI, 7.4-8.6 years; absolute difference, -2.4 years, 95% CI, -1.5 to -3.2 years) for patients with a 43- to 49-day TS-RT, and 6.5 years (95% CI, 6.1-6.8 years; absolute difference, -4.1 years, 95% CI, -3.4 to -4.7 years) for those with a 50-days or more TS-RT. Multivariable analysis found that compared with a 42-days or less TS-RT, there was not a significant increase in mortality with a 43- to 49-day TS-RT (HR, 0.98; 95% CI, 0.93-1.04), although there was for a TS-RT of 50 days or more (HR, 1.07; 95% CI, 1.02-1.12). A significant interaction was identified between TS-RT and disease site. Subgroup effect modeling found that a delayed TS-RT of 7 days resulted in significantly worse OS for patients with tonsil tumors (HR, 1.22; 95% CI, 1.05-1.43) though not other tumor subtypes. Accelerated fractionation of 5.2 fractions or more per week was associated with improved survival (HR, 0.93; 95% CI, 0.87-0.99) compared with standard fractionation. CONCLUSIONS AND RELEVANCE: Delayed TS-RT of 50 days or more was associated with worse overall survival. The multidisciplinary care team should focus on shortening TS-RT to improve survival. Unavoidable delays may be an indication for accelerated fractionation or other dose intensification strategies.
Authors: Silke Tribius; Johanna Donner; Henning Pazdyka; Adrian Münscher; Alexander Gröbe; Cordula Petersen; Andreas Krüll; Pierre Tennstedt Journal: Head Neck Date: 2016-02-13 Impact factor: 3.147
Authors: C Robertson; A G Robertson; J H Hendry; S A Roberts; N J Slevin; W B Duncan; R H MacDougall; G R Kerr; B O'Sullivan; T J Keane Journal: Int J Radiat Oncol Biol Phys Date: 1998-01-15 Impact factor: 7.038
Authors: Talha Shaikh; Elizabeth A Handorf; Colin T Murphy; Ranee Mehra; John A Ridge; Thomas J Galloway Journal: Int J Radiat Oncol Biol Phys Date: 2016-09-06 Impact factor: 7.038
Authors: Michel C van Harten; Frank J P Hoebers; Kenneth W Kross; Erik D van Werkhoven; Michiel W M van den Brekel; Boukje A C van Dijk Journal: Oral Oncol Date: 2014-12-22 Impact factor: 5.337
Authors: David I Rosenthal; Li Liu; Jason H Lee; Neha Vapiwala; Ara A Chalian; Gregory S Weinstein; Irina Chilian; Randal S Weber; Mitchell Machtay Journal: Head Neck Date: 2002-02 Impact factor: 3.147
Authors: L J Peters; H Goepfert; K K Ang; R M Byers; M H Maor; O Guillamondegui; W H Morrison; R S Weber; A S Garden; R A Frankenthaler Journal: Int J Radiat Oncol Biol Phys Date: 1993-04-30 Impact factor: 7.038
Authors: Roy Xiao; Rohan R Joshi; Qasim Husain; Jennifer R Cracchiolo; Nancy Lee; Jillian Tsai; Yao Yu; Linda Chen; Jung J Kang; Sean McBride; Nadeem Riaz; Benjamin R Roman; Ian Ganly; Viviane Tabar; Stacey T Gray; Marc A Cohen Journal: Head Neck Date: 2019-07-11 Impact factor: 3.147
Authors: Michael C Jin; Siyu Shi; Adela Wu; Navjot Sandhu; Michael Xiang; Scott G Soltys; Susan Hiniker; Gordon Li; Erqi L Pollom Journal: Neurooncol Pract Date: 2020-06-18
Authors: Andrew J Bishop; J Andrew Livingston; Matt S Ning; Isaac D Valdez; Cody A Wages; Mary Fran McAleer; Arnold C Paulino; David R Grosshans; Kristina D Woodhouse; Randa Tao; Michael E Roth; G Brandon Gunn; Susan L McGovern Journal: Int J Radiat Oncol Biol Phys Date: 2021-03-04 Impact factor: 8.013
Authors: Sung Jun Ma; Oluwadamilola T Oladeru; Joseph A Miccio; Austin J Iovoli; Gregory M Hermann; Anurag K Singh Journal: JAMA Netw Open Date: 2019-08-02
Authors: Chandler J Rygalski; Songzhu Zhao; Antoine Eskander; Kevin Y Zhan; Edmund A Mroz; Guy Brock; Dustin A Silverman; Dukagjin Blakaj; Marcelo R Bonomi; Ricardo L Carrau; Matthew O Old; James W Rocco; Nolan B Seim; Sidharth V Puram; Stephen Y Kang Journal: Ann Surg Oncol Date: 2020-11-13 Impact factor: 5.344
Authors: Flora Yan; Hong Li; John R de Almeida; John M Kaczmar; Patrik Pipkorn; Joseph Zenga; Mary S Richardson; David M Neskey; Anand K Sharma; Terry A Day; Evan M Graboyes Journal: Otolaryngol Head Neck Surg Date: 2021-02-23 Impact factor: 5.591
Authors: Evan M Graboyes; Katherine R Sterba; Hong Li; Graham W Warren; Anthony J Alberg; Elizabeth A Calhoun; Brian Nussenbaum; Jessica McCay; Courtney H Marsh; Nosayaba Osazuwa-Peters; David M Neskey; John M Kaczmar; Anand K Sharma; Jennifer Harper; Terry A Day; Chanita Hughes-Halbert Journal: JCO Oncol Pract Date: 2021-03-10
Authors: Robert P Takes; Gyorgy B Halmos; John A Ridge; Paolo Bossi; Matthias A W Merkx; Alessandra Rinaldo; Alvaro Sanabria; Ludi E Smeele; Antti A Mäkitie; Alfio Ferlito Journal: Curr Oncol Rep Date: 2020-07-10 Impact factor: 5.075
Authors: Ahmed I Ghanem; Matthew Schymick; Souheyla Bachiri; Aniruddh Mannari; Jawad Sheqwara; Charlotte Burmeister; Steven Chang; Tamer Ghanem; Farzan Siddiqui Journal: World J Otorhinolaryngol Head Neck Surg Date: 2019-01-11